Global Allergic Conjunctivitis Market, Patients, Treated Patients, by Countries (India, China, Japan, US, UK, etc), Disease Type (SAC, PAC, VKC, AKC, GPC), Drugs Profile (Zerviate, OTX-DP, ADX-102, PRT-2761, etc) Companies, Growth Drivers & Challenges

January 2019 | | ID: GE1F93FB7A0EN
Renub Research

Abstracts

Allergic conjunctivitis is a kind of eye disease in which it affect the eye surfaces and are commonly associated to immune-mediated inflammatory reactions of these structures. The prevalence of the allergic conjunctivitis is found more in summer and spring across the various regions. Pollen, dust, irritants such as cigarette smoke, perfumes etc. are some of the substance that triggers the conjunctivitis. Itching is the most typical sign of allergic conjunctivitis, and more than 75 percent of patients report this symptom when seeking treatment. According to Renub Research Allergic Conjunctivitis Market is expected to be more than USD 2 Billion market by 2025.

Global allergic conjunctivitis market will grow due to increasing prevalence of various allergic conjunctivitis, development in medical infrastructure in the developing countries, growing awareness about allergic conjunctivitis among people, increasing ageing population and upcoming therapies such as Zerviate, ADX-102, PRT-2761, OTX-DP etc. Allergic conjunctivitis are classified mainly in five types: Seasonal Allergic Conjunctivitis (SAC), Perennial Allergic Conjunctivitis (PAC), Vernal Keratoconjunctivitis (VKC), Atopic Keratoconjunctivitis (AKC) and Giant Papillary Conjunctivitis (GPC).

Renub Research report titled “Global Allergic Conjunctivitis Market, Patients, Treated Patients By Countries (India, China, Japan, United States, United Kingdom, France, Germany, Italy, Spain), Disease Type (Seasonal Allergic Conjunctivitis (SAC) & Perennial Allergic Conjunctivitis (PAC), Vernal Keratoconjunctivitis (VKC), Atopic Keratoconjunctivitis (AKC) And Giant Papillary Conjunctivitis (GPC)), Drugs Profile (Zerviate, OTX-DP, ADX-102, PRT-2761, CVXL-0074, AK-002, Bertilimumab, Reproxalap, ST-266, SYL-116011) Companies (Santen Pharmaceutical, Alcon (Novartis), Portola Pharmaceuticals, Ocular Therapeutix), Growth Drivers, Challenges” provides a complete analysis of global allergic conjunctivitis market.

China Dominates the Global Allergic Conjunctivitis Patient Population

In this report, we have shown complete insight of country analysis of allergic conjunctivitis patient population. The covered countries are; India, China, Japan, United States, United Kingdom, France, Germany, Italy and Spain. China dominates the global allergic conjunctivitis patient population numbers.

United States is the leading Country in the Global Allergic Conjunctivitis Market

Allergic conjunctivitis market is growing across all parts of the world. Market growth rates varies in the countries covered in the report India, China, Japan, United States, United Kingdom, France, Germany, Italy and Spain. United States is leading country in the global allergic conjunctivitis market due to growing awareness, strong healthcare support system and large patient population.

Seasonal Allergic Conjunctivitis (SAC) & Perennial Allergic Conjunctivitis (PAC) Hold Majority of Market in the Global Allergic Conjunctivitis Market

On the basis of disease type, global Allergic conjunctivitis market is further segmented into seasonal allergic conjunctivitis (SAC) & perennial allergic conjunctivitis (PAC) market, vernal keratoconjunctivitis (VKC) market, atopic keratoconjunctivitis (AKC) market and giant papillary conjunctivitis (GPC) market, globally. Seasonal allergic conjunctivitis (SAC) & perennial allergic conjunctivitis (PAC) hold majority of market share in the global allergic conjunctivitis market.

Allergic Conjunctivitis Pipe Line Drugs are Key Strength for this Market Place

In the global allergic conjunctivitis market, allergic conjunctivitis pipe line drugs will play the major role for the growth of this market. At present several drugs such as Zerviate, OTX-DP, ADX-102, PRT-2761, CVXL-0074, AK-002, Bertilimumab, Reproxalap, ST-266, SYL-116011 etc. are in preclinical, IND, Phase I, Phase II and Phase III stage.

Report has been analyzed from 9 Major Viewpoints

1. Global Allergic Conjunctivitis Market
2. Global Allergic Conjunctivitis Market Share, Disease Type Market Share, Patients Share, Treated Patients Share
3. Country Allergic Conjunctivitis Market
4. Country Allergic Conjunctivitis Patients Population
5. Country Allergic Conjunctivitis Treated Patients Population
6. Disease Type Allergic Conjunctivitis Market
7. Allergic Conjunctivitis Drugs Pipeline
8. Growth Drivers and Challenges
9. Key Allergic Conjunctivitis Companies Initiatives and Financial Insight

Country Covered – Global Allergic Conjunctivitis Market

• India
• China
• Japan
• United States
• United Kingdom
• France
• Germany
• Italy
• Spain

Disease Type Covered – Global Allergic Conjunctivitis Market

• Seasonal Allergic Conjunctivitis (SAC) & Perennial Allergic Conjunctivitis (PAC)
• Vernal Keratoconjunctivitis (VKC)
• Atopic Keratoconjunctivitis (AKC)
• Giant Papillary Conjunctivitis (GPC)

Drugs Profile Covered – Global Allergic Conjunctivitis Market

• Zerviate
• OTX-DP
• ADX-102
• PRT-2761
• CVXL-0074
• AK-002
• Bertilimumab
• Reproxalap
• ST-266
• SYL-116011

Company Covered

• Santen Pharmaceutical
• Alcon (Novartis)
• Portola Pharmaceuticals
• Ocular Therapeutix

Contents

1. EXECUTIVE SUMMARY

2. GLOBAL ALLERGIC CONJUNCTIVITIS MARKET AND PATIENTS ANALYSIS

2.1 Allergic Conjunctivitis Market
2.2 Allergic Conjunctivitis Patient Numbers
2.3 Allergic Conjunctivitis Treated Patient Numbers

3. SHARE ANALYSIS – GLOBAL ALLERGIC CONJUNCTIVITIS

3.1 Country Market Share
3.2 Patients Population Share
3.3 Treated Patients Population Share
3.4 By Disease Type Share

4. INDIA

4.1 Allergic Conjunctivitis Patient Numbers
4.2 Allergic Conjunctivitis Treated Patient Numbers
4.3 Allergic Conjunctivitis Market

5. CHINA

5.1 Allergic Conjunctivitis Patient Numbers
5.2 Allergic Conjunctivitis Treated Patient Numbers
5.3 Allergic Conjunctivitis Market

6. JAPAN

6.1 Allergic Conjunctivitis Patient Numbers
6.2 Allergic Conjunctivitis Treated Patient Numbers
6.3 Allergic Conjunctivitis Market

7. UNITED STATES

7.1 Allergic Conjunctivitis Patient Numbers
7.2 Allergic Conjunctivitis Treated Patient Numbers
7.3 Allergic Conjunctivitis Market

8. UNITED KINGDOM

8.1 Allergic Conjunctivitis Patient Numbers
8.2 Allergic Conjunctivitis Treated Patient Numbers
8.3 Allergic Conjunctivitis Market

9. FRANCE

9.1 Allergic Conjunctivitis Patient Numbers
9.2 Allergic Conjunctivitis Treated Patient Numbers
9.3 Allergic Conjunctivitis Market

10. GERMANY

10.1 Allergic Conjunctivitis Patient Numbers
10.2 Allergic Conjunctivitis Treated Patient Numbers
10.3 Allergic Conjunctivitis Market

11. ITALY

11.1 Allergic Conjunctivitis Patient Numbers
11.2 Allergic Conjunctivitis Treated Patient Numbers
11.3 Allergic Conjunctivitis Market

12. SPAIN

12.1 Allergic Conjunctivitis Patient Numbers
12.2 Allergic Conjunctivitis Treated Patient Numbers
12.3 Allergic Conjunctivitis Market

13. DISEASE TYPE – GLOBAL ALLERGIC CONJUNCTIVITIS MARKET

13.1 Seasonal Allergic Conjunctivitis (SAC) & Perennial Allergic Conjunctivitis (PAC)
13.2 Vernal Keratoconjunctivitis (VKC)
13.3 Atopic Keratoconjunctivitis (AKC)
13.4 Giant Papillary Conjunctivitis (GPC)

14. GLOBAL ALLERGIC CONJUNCTIVITIS DRUGS PROFILE/PIPE LINE DRUGS

14.1 Zerviate
14.2 OTX-DP (Dexamethasone Insert)
14.3 ADX-102
14.4 PRT2761
14.5 CVXL-0074
14.6 AK-002
14.7 Bertilimumab
14.8 Reproxalap
14.9 ST-266
14.10 SYL-116011

15. GROWTH DRIVER

15.1 Rapid Urbanization and Growth of Particulate Pollution
15.2 Increasing Ageing Population & Widespread Use of Medications for Various Eye Diseases

16. CHALLENGES

16.1 Diagnostic Challenges
16.2 Undertreated by Patients

17. SANTEN PHARMACEUTICAL

17.1 Company Overview
17.2 Initiatives
  17.2.1 Point
  17.2.2 Point
17.3 Financial Insight

18. ALCON INC. (NOVARTIS)

18.1 Company Overview
18.2 Initiatives
  18.2.1 Point
  18.2.2 Point
18.3 Financial Insight

19. PORTOLA PHARMACEUTICALS INC.

19.1 Company Overview
19.2 Initiatives
  19.2.1 Point
  19.2.2 Point
19.3 Financial Insight

20. OCULAR THERAPEUTIX INC.

20.1 Company Overview
20.2 Initiatives
  20.2.1 Point
  20.2.2 Point
20.3 Financial Insight

List Of Figures

LIST OF FIGURES:

Figure 2 1: Global - Allergic Conjunctivitis Market (Million US$), 2013 – 2018
Figure 2 2: Global – Forecast for Allergic Conjunctivitis Market (Million US$), 2019 – 2025
Figure 2 3: Global - Allergic Conjunctivitis Patient Numbers (Million), 2013 – 2018
Figure 2 4: Global – Forecast for Allergic Conjunctivitis Patient Numbers (Million), 2019 – 2025
Figure 2 5: Global - Allergic Conjunctivitis Treated Patient Numbers (Million), 2013 – 2018
Figure 2 6: Global – Forecast for Allergic Conjunctivitis Treated Patient Numbers (Million), 2019 – 2025
Figure 3 1: Global - Allergic Conjunctivitis Market Country Share (Percent), 2013 – 2018
Figure 3 2: Global – Forecast for Allergic Conjunctivitis Market Country Share (Percent), 2019 – 2025
Figure 3 3: Global - Allergic Conjunctivitis Treated Patients Population Country Share (Percent), 2013 – 2018
Figure 3 4: Global – Forecast for Allergic Conjunctivitis Treated Patients Population Country Share (Percent), 2019 – 2025
Figure 3 5: Global - Allergic Conjunctivitis Disease Type Market Share (Percent), 2013 – 2018
Figure 3 6: Global – Forecast for Allergic Conjunctivitis Disease Type Market Share (Percent), 2019 – 2025
Figure 4 1: India - Allergic Conjunctivitis Patient Numbers (Million), 2013 – 2018
Figure 4 2: India – Forecast for Allergic Conjunctivitis Patient Numbers (Million), 2019 – 2025
Figure 4 3: India - Allergic Conjunctivitis Treated Patient Numbers (Million), 2013 – 2018
Figure 4 4: India – Forecast for Allergic Conjunctivitis Treated Patient Numbers (Million), 2019 – 2025
Figure 4 5: India - Allergic Conjunctivitis Market (Million US$), 2013 – 2018
Figure 4 6: India – Forecast for Allergic Conjunctivitis Market (Million US$), 2019 – 2025
Figure 5 1: China - Allergic Conjunctivitis Patient Numbers (Million), 2013 – 2018
Figure 5 2: China – Forecast for Allergic Conjunctivitis Patient Numbers (Million), 2019 – 2025
Figure 5 3: China - Allergic Conjunctivitis Treated Patient Numbers (Million), 2013 – 2018
Figure 5 4: China – Forecast for Allergic Conjunctivitis Treated Patient Numbers (Million), 2019 – 2025
Figure 5 5: China - Allergic Conjunctivitis Market (Million US$), 2013 – 2018
Figure 5 6: China – Forecast for Allergic Conjunctivitis Market (Million US$), 2019 – 2025
Figure 6 1: Japan - Allergic Conjunctivitis Patient Numbers (Million), 2013 – 2018
Figure 6 2: Japan – Forecast for Allergic Conjunctivitis Patient Numbers (Million), 2019 – 2025
Figure 6 3: Japan - Allergic Conjunctivitis Treated Patient Numbers (Million), 2013 – 2018
Figure 6 4: Japan – Forecast for Allergic Conjunctivitis Treated Patient Numbers (Million), 2019 – 2025
Figure 6 5: Japan - Allergic Conjunctivitis Market (Million US$), 2013 – 2018
Figure 6 6: Japan – Forecast for Allergic Conjunctivitis Market (Million US$), 2019 – 2025
Figure 7 1: United States - Allergic Conjunctivitis Patient Numbers (Million), 2013 – 2018
Figure 7 2: United States – Forecast for Allergic Conjunctivitis Patient Numbers (Million), 2019 – 2025
Figure 7 3: United States - Allergic Conjunctivitis Treated Patient Numbers (Million), 2013 – 2018
Figure 7 4: United States – Forecast for Allergic Conjunctivitis Treated Patient Numbers (Million), 2019 – 2025
Figure 7 5: United States - Allergic Conjunctivitis Market (Million US$), 2013 – 2018
Figure 7 6: United States – Forecast for Allergic Conjunctivitis Market (Million US$), 2019 – 2025
Figure 8 1: United Kingdom - Allergic Conjunctivitis Patient Numbers (Million), 2013 – 2018
Figure 8 2: United Kingdom – Forecast for Allergic Conjunctivitis Patient Numbers (Million), 2019 – 2025
Figure 8 3: United Kingdom - Allergic Conjunctivitis Treated Patient Numbers (Million), 2013 – 2018
Figure 8 4: United Kingdom – Forecast for Allergic Conjunctivitis Treated Patient Numbers (Million), 2019 – 2025
Figure 8 5: United Kingdom - Allergic Conjunctivitis Market (Million US$), 2013 – 2018
Figure 8 6: United Kingdom – Forecast for Allergic Conjunctivitis Market (Million US$), 2019 – 2025
Figure 9 1: France - Allergic Conjunctivitis Patient Numbers (Million), 2013 – 2018
Figure 9 2: France – Forecast for Allergic Conjunctivitis Patient Numbers (Million), 2019 – 2025
Figure 9 3: France - Allergic Conjunctivitis Treated Patient Numbers (Million), 2013 – 2018
Figure 9 4: France – Forecast for Allergic Conjunctivitis Treated Patient Numbers (Million), 2019 – 2025
Figure 9 5: France - Allergic Conjunctivitis Market (Million US$), 2013 – 2018
Figure 9 6: France – Forecast for Allergic Conjunctivitis Market (Million US$), 2019 – 2025
Figure 10 1: Germany - Allergic Conjunctivitis Patient Numbers (Million), 2013 – 2018
Figure 10 2: Germany – Forecast for Allergic Conjunctivitis Patient Numbers (Million), 2019 – 2025
Figure 10 3: Germany - Allergic Conjunctivitis Patient Treated Numbers (Million), 2013 – 2018
Figure 10 4: Germany – Forecast for Allergic Conjunctivitis Treated Patient Numbers (Million), 2019 – 2025
Figure 10 5: Germany - Allergic Conjunctivitis Market (Million US$), 2013 – 2018
Figure 10 6: Germany – Forecast for Allergic Conjunctivitis Market (Million US$), 2019 – 2025
Figure 11 1: Italy - Allergic Conjunctivitis Patient Numbers (Million), 2013 – 2018
Figure 11 2: Italy – Forecast for Allergic Conjunctivitis Patient Numbers (Million), 2019 – 2025
Figure 11 3: Italy - Allergic Conjunctivitis Treated Patient Numbers (Million), 2013 – 2018
Figure 11 4: Italy – Forecast for Allergic Conjunctivitis Treated Patient Numbers (Million), 2019 – 2025
Figure 11 5: Italy - Allergic Conjunctivitis Market (Million US$), 2013 – 2018
Figure 11 6: Italy – Forecast for Allergic Conjunctivitis Market (Million US$), 2019 – 2025
Figure 12 1: Spain - Allergic Conjunctivitis Patient Numbers (Million), 2013 – 2018
Figure 12 2: Spain – Forecast for Allergic Conjunctivitis Patient Numbers (Million), 2019 – 2025
Figure 12 3: Spain - Allergic Conjunctivitis Treated Patient Numbers (Million), 2013 – 2018
Figure 12 4: Spain – Forecast for Allergic Conjunctivitis Treated Patient Numbers (Million), 2019 – 2025
Figure 12 5: Spain - Allergic Conjunctivitis Market (Million US$), 2013 – 2018
Figure 12 6: Spain – Forecast for Allergic Conjunctivitis Market (Million US$), 2019 – 2025
Figure 13 1: Global - Seasonal Allergic Conjunctivitis (SAC) & Perennial Allergic Conjunctivitis (PAC) Market (Million US$), 2013 – 2018
Figure 13 2: Global – Forecast for Seasonal Allergic Conjunctivitis (SAC) & Perennial Allergic Conjunctivitis (PAC) Market (Million US$), 2019 – 2025
Figure 13 3: Global - Vernal Keratoconjunctivitis (VKC) Market (Million US$), 2013 – 2018
Figure 13 4: Global – Forecast for Vernal Keratoconjunctivitis (VKC) Market (Million US$), 2019 – 2025
Figure 13 5: Global - Atopic Keratoconjunctivitis (AKC) Market (Million US$), 2013 – 2018
Figure 13 6: Global – Forecast for Atopic Keratoconjunctivitis (AKC) Market (Million US$), 2019 – 2025
Figure 13 7: Global - Giant Papillary Conjunctivitis (GPC) Market (Million US$), 2013 – 2018
Figure 13 8: Global – Forecast for Giant Papillary Conjunctivitis (GPC) Market (Million US$), 2019 – 2025
Figure 14 1: Allergic Conjunctivitis Pipe Line Drug – Zerviate Status (2018)
Figure 14 2: Allergic Conjunctivitis Pipe Line Drug – OTX-DP (Dexamethasone Insert) Status (2018)
Figure 14 3: Allergic Conjunctivitis Pipe Line Drug – ADX-102 Status (2018)
Figure 14 4: Allergic Conjunctivitis Pipe Line Drug – PRT-2761Status (2018)
Figure 14 5: Allergic Conjunctivitis Pipe Line Drug – CVXL-0074 Status (2018)
Figure 14 6: Allergic Conjunctivitis Pipe Line Drug – AK-002 Status (2018)
Figure 14 7: Allergic Conjunctivitis Pipe Line Drug – Bertilimumab Status (2018)
Figure 14 8: Allergic Conjunctivitis Pipe Line Drug – Reproxalap Status (2018)
Figure 14 9: Allergic Conjunctivitis Pipe Line Drug – ST-266 Status (2018)
Figure 14 10: Allergic Conjunctivitis Pipe Line Drug – SYL-116011 Status (2018)
Figure 17 1: Santen Pharmaceutical – Global Revenue (Million US$), 2014 - 2018
Figure 17 2: Santen Pharmaceutical – Forecast for Global Revenue (Million US$), 2019 - 2025
Figure 18 1: Alcon (Novartis) – Global Revenue (Million US$), 2014 - 2018
Figure 18 2: Alcon (Novartis) – Forecast for Global Revenue (Million US$), 2019 - 2025
Figure 19 1: Portola Pharmaceuticals – Global Revenue (Thousand US$), 2014 - 2018
Figure 19 2: Portola Pharmaceuticals – Forecast for Global Revenue (Thousand US$), 2019 - 2025
Figure 20 1: Ocular Therapeutix – Global Revenue (Thousand US$), 2014 - 2018
Figure 20 2: Ocular Therapeutix – Forecast for Global Revenue (Thousand US$), 2019 - 2025

List Of Tables

LIST OF TABLES:

Table 3 1: Global - Allergic Conjunctivitis Patients Population Country Share (Percent), 2013 – 2018
Table 3 2: Global – Forecast for Allergic Conjunctivitis Patients Population Country Share (Percent), 2019 – 2025